Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions by Chamaida Plasencia et al.
ORIGINAL RESEARCH
published: 08 October 2015
doi: 10.3389/fmed.2015.00071
Edited by:
Burkhard Franz Leeb,
State Hospital Stockerau, Austria
Reviewed by:
Rebecca Fischer-Betz,
Heinrich Heine University Düsseldorf,
Germany
Jianhua Mao,
The Children’s Hospital of Zhejiang
University School of Medicine, China
*Correspondence:
Chamaida Plasencia
chamiplaro@gmail.com
Specialty section:
This article was submitted to
Rheumatology, a section of the
journal Frontiers in Medicine
Received: 24 July 2015
Accepted: 17 September 2015
Published: 08 October 2015
Citation:
Plasencia C, Jurado T, Villalba A,
Peitedado D, Casla MTL, Nuño L,
Bonilla MG, Martínez-Feito A,
Martín-Mola E, Pascual-Salcedo D
and Balsa A (2015) Effect of infliximab
dose increase in rheumatoid arthritis
at different trough concentrations: a
cohort study in clinical practice
conditions.
Front. Med. 2:71.
doi: 10.3389/fmed.2015.00071
Effect of infliximab dose increase in
rheumatoid arthritis at different
trough concentrations: a cohort
study in clinical practice conditions
Chamaida Plasencia1*, Teresa Jurado2, Alejandro Villalba1, Diana Peitedado1,
Maria Teresa López Casla2, Laura Nuño1, María Gema Bonilla1, Ana Martínez-Feito2,
Emilio Martín-Mola1, Dora Pascual-Salcedo2 and Alejandro Balsa1
1 Rheumatology Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain, 2 Immunology
Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain
Background: Evidence supporting treatment intensification in rheumatoid arthritis (RA)
is limited and controversial. We explored outcomes of infliximab dose increases and
accounted for pre-existing trough levels in patients with active RA.
Methods: This study was a retrospective study of 42 RA patients who received increased
infliximab following an insufficient response (DAS28 >3.2). Serum concentrations of
infliximab and antibodies to infliximab (ATI) and DAS28 and EULAR clinical response
parameters were recorded for 1 year. Analyses were performed in three patient groups
that were defined by infliximab serum concentration prior to treatment enhancement: no
detectable, low (<1.1μg/mL) or high (1.1μg/mL) drug levels.
Results: No circulating infliximab was detected in 20 patients (47.6%), but 13 (31%) and
9 (21.4%) patients exhibited low and high levels, respectively. ATI was only detected in
patients with no detectable drug levels because the drug interferes with ELISA. DAS28
disease activity globally showed a modest improvement after dose escalation, but this
improvement did not persist after 6 and 12months. Infliximab serum levels increased
significantly in the high group (p=0.016), but no increase was achieved in the low and
no detectable groups. The three study groups exhibited similar disease activity over time,
and no improvement was observed in the non-responder EULAR rates.
Conclusion: These results suggest that the efficacy of an infliximab dose increase is
limited, and the response is independent of the infliximab trough serum concentration
that is achieved prior to escalation.
Keywords: rheumatoid arthritis, infliximab, dose increase, clinical efficacy
Introduction
The response to tumor necrosis factor (TNF) inhibitor treatment in chronic inflammatory diseases
exhibits great therapeutic variability. Failure to respond to anti-TNF therapy may occur at treatment
onset, or it may be secondary to an initial improvement (1, 2). A concentration-dependent effect
was described for anti-TNF treatment (3, 4), and inadequate serum trough drug levels is a major
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cause for non-responsiveness (3). The development of anti-drug
antibodies [antibodies to infliximab (ATI)] is a major source of
drug clearance, and it is associated with lower serum drug levels
and lack of response (5). However, an optimal therapeutic con-
centration is not defined, and empirical algorithms for treatment
optimization prevail (6). A change in therapeutic target would
be appropriate in non-improving patients with high circulating
infliximab (Ifx) levels, and switching to another TNF inhibitorwas
proposed in patients who present no free drug levels and with
detectable anti-drug antibodies following treatment. However,
increasing the dose of anti-TNF treatment when drug levels are
low may achieve a threshold therapeutic concentration (7, 8), and
this approach was effective in inflammatory bowel disease (9).
Evidence supporting dose intensification in rheumatoid arthri-
tis (RA) is limited and controversial, and few studies relate
dose intensification with pre-increase serum trough drug levels
(10–12).
The present study retrospectively analyzed the effect of Ifx
dose increase in RA non-responders and accounted for previous
drug concentrations to further elucidate the utility of proposed
algorithms for patients who do not respond to the first anti-TNF
therapy.
Materials and Methods
A retrospective observational study was conducted of RA patients
included in the Hospital Universitario La Paz Biologics Registry
(Madrid, Spain) who started treatment with Ifx as the first TNF-
blocking agent. The following inclusion criteria were used: RA
patients (older than 18 years) treated from 2005 to 2011 who
exhibited an insufficient clinical response defined as DAS28>3.2,
who received an increase in the dose of Ifx, and who had serum
sample and clinical assessment data during the first year of treat-
ment. The period of inclusion ended in 2011 because no increase
in Ifx dose was used in our clinic after this time. A final observa-
tion was carried forward for analysis in patients who stopped Ifx
treatment within the first year after dose increase.
Ifx treatment could be combined with classic disease-
modifying anti-rheumatic drugs (DMARDs) and/or
corticosteroids. The research ethics committee of the Hospital
Universitario La Paz (Madrid, Spain) approved the study, and
informed consent was obtained for the storage and future use of
serum samples.
Treatment
Patients were initially treated with 3mg/kg Ifx intravenously at
weeks 0, 2, 6, and 14 and every 8weeks thereafter. The dose of
Ifx was increased via the administration of 4, 5, or 6mg/kg Ifx
or a reduction in the administration interval to 7 or 6weeks,
with a maximum dose of 6mg/kg every 6weeks. Dose escalation
could also be combined with increasing doses of DMARDs and/or
corticosteroids.
Data Collection and Assessments
Medical history, demographic data, anti-citrullinated protein
antibodies (ACPA), and rheumatoid factor (RF) were retrospec-
tively retrieved prior to Ifx increase (baseline). DAS28 score,
EULAR response, and serum concentrations of Ifx and ATI were
also retrieved at baseline (T1), after the first Ifx dose increment
(T2), and at 6months (T3), and 12months (T4). ACPAwere mea-
sured using ELISA (Eurodiagnostica, Malmo, Sweden), and RF
was assessed using nephelometry (Siemens, Marburg, Germany)
with cut-off values of 25 and 9 IU/mL.DAS28was calculated using
the erythrocyte sedimentation rate (ESR), and the response to Ifx
was evaluated using the European League Against Rheumatism
(EULAR) criteria (13).
Infliximab Serum and ATI Concentrations
Serum Ifx concentrations were determined using a capture ELISA
as described previously (14), but a biotinylated monoclonal
anti-Ifx idiotype antibody (Progenika Bipopharma S.A., Vizcaya,
Spain) was used instead of a rabbit antibody to detect Ifx. Serum
ATI levels were assayed using a two-site (bridging) in-house
ELISA (15) with a cut-off for positivity of 50 arbitrary units
(AU)/mL.
Statistical Analysis
Descriptive statistics are provided as the mean, SD, median and
interquartile range (IQR). A fixed effects analysis of repeated
measures was performed, and Bonferroni correction was used
for multiple comparisons. Qualitative variables were compared at
different time points and between different groups using Fisher’s
test, and the Bonferroni test was used for multiple comparisons.
A regression mixed model for repeated measurements was
performed using group (no, low, and high IFX levels) and time
points (T1, T2, T3, and T4) as factors to compare DAS28 and
delta-DAS28 between groups. Interactions between factors were
calculated as fixed effects, and subjects were calculated as random
effects. Pair-wise comparisons were calculated using Bonferroni
correction. EULARwas analyzed using a generalized linearmodel
with cumulative logit link function.A significance level of 0.05was
used for statistical testing, and all analyses were performed using
SAS 9.3 (SAS Institute, Cary, NC, USA).
Patients were assigned to one of three serum Ifx groups: no
detectable, low (<1.1μg/mL) or high (1.1μg/mL). These cut-
off levels were based on the observation that serum Ifx >1mg/L
(12) was associated with improved disease (16).
Results
Patient Characteristics
Forty-two patients (37women)were included in the study. Twenty
patients exhibited no detectable free Ifx, 13 patients exhibited Low
levels, and 9 patients exhibited High levels. Table 1 shows the
descriptive statistics.
The age of disease onset was significantly lower in patients with
no detectable drug levels, and the duration of Ifx treatment was
significantly longer for patients with High drug levels. Sixteen
patients in the no free Ifx group received an increased Ifx dose, and
the treatment interval was reduced in eight patients. Eleven and
nine patients in the low and high groups, respectively, received
an increased Ifx dose, and the treatment interval was reduced
in five and four patients, respectively. Both strategies were used
simultaneously in some patients, and these numbers are higher.
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TABLE 1 | Demographic and clinical characteristics of patients.
Total study
population (n=42)
No detectable
Ifx levels (n=20)
Low
Ifx levels (n=13)
High
Ifx levels (n=9)
Age at onset (years), meanSD 57.114.0 49.614.5 61.610.8 67.46.1
Female, n (%) 37 (88.1) 19 (95) 9 (69.2) 9 (100)
Disease duration (years), meanSD 19.410.4 16.36.3 17.910.1 28.313.8
Duration of Ifx treatment (years), median (IQR) 6.2 (1–13) 4.25 (1.23–8.63) 6.25 (4.38–10.75) 8.25 (8.25–10.25)
ACPA-positive, n (%) 36 (85.7) 19 (95) 12 (92.3) 5 (55.6)
RF-positive, n (%) 35 (83.3) 18 (90) 10 (76.9) 7 (77.8)
Methotrexate therapy, n (%) 36 (85.7) 16 (80) 12 (92.3) 8 (88.8)
Methotrexate dose (mg/week), median (IQR) 12.5 (0–25) 15.0 (0–15) 15 (0–20) 10 (0–15)
Other DMARDs, n (%) 18 (42.9) 9 (21.4) 4 (9.2) 5 (11.9)
Concomitant use of glucocorticoids, n (%) 28 (66.6) 13 (30.9) 8 (19) 7 (16.6)
Prednisone dose (mg/day) before Ifx increase, meanSD 6.25.2 5.76.8 4.23.2 7.06.4
Prednisone dose (mg/day) at one year, meanSD 7.96.3 8.77.6 7.16.3 8.25.6
DAS28 at the start Ifx treatment, meanSD 5.501.20 5.681.29 5.031.04 5.771.12
Baseline DAS28 before Ifx increase, meanSD 4.551.01 4.910.73 3.720.90 4.971.06
Trough Ifx levels before dose increase (μg/mL), median (IQR) 94.5 (0–10.5) ND 574 (16–1024) 2112 (1152–10464)
ATI levels before Ifx increase, AU/mL, median (IQR) 0 (0–60000) 1068.5 (377.5–12328.0) 0 (0–0) ND
Ifx, Infliximab; SD, standard deviation; IQR, interquartile range; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DMARDs, disease-modifying anti-rheumatic drugs;
DAS28, disease activity score in 28 joints; ATI, anti-infliximab antibodies; AU/mL, arbitrary units per milliliter; ND, not detectable.
FIGURE 1 | (A) Changes in DAS28 over time in all patients. T1 (baseline), T2 (post-Ifx dose increment), T3 (at 6months), T4 (at 12months). *p<0.05 vs. DAS28 in
T1 after Bonferroni correction. (B) DAS28 and delta-DAS28 from T1 in patients with no, low and high Ifx serum concentrations at baseline. T1 (baseline), T2 (post-Ifx
dose increment), T3 (at 6months), T4 (at 12months).
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FIGURE 2 | (A) Ifx levels and (B) ATI levels in patients with no, low, and high Ifx serum concentrations at baseline. T1 (baseline), T2 (post-Ifx dose increment), T3 (at
6months), T4 (at 12months).
Five patients did not complete the year of treatment because of
insufficient clinical response (three patients) and side effects (two
patients, pneumonia and skin infection).
Effectiveness of Infliximab Dose Increase
Baseline DAS28 for the entire study population (Figure 1A)
improved immediately after dose increase from baseline
(4.55 1.01 vs. 3.95 1.22; p< 0.05), but this decrease in
DAS28 disappeared at 12months (3.98 1.22; p= 0.075). The
change in DAS28 from baseline (delta-DAS28) demonstrated
significant disease worsening (from  0.63 1.18 post-increase
to 1.17 1.45 after 12months (p< 0.001). Figure 1B shows
the DAS28 and delta-DAS28 progression for individual patient
groups. Basal disease activity was lowest in the low group
(3.7 0.9) vs. 4.9 0.7 (p= 0.001) and 4.9 1.1 (p= 0.006)
in the no detectable and high drug level groups, respectively).
No significant change in DAS28 was observed in any of the
individual patient groups throughout the study. The decrease
in disease activity from the time of post-Ifx dose increase
was significant in patients with no detectable Ifx levels after
12months (mean delta-DAS28: 1.0 1.9 vs. 0.7 1.0, p< 0.05)
and patients with high Ifx levels (mean delta-DAS28: 1.3 1.3 vs.
 1.0 1.3; p< 0.05).
European League Against Rheumatism response rates in all
three patient groups revealed no significant differences at any time
point with 11.1, 16.7, and 12.5% of patients in the no, low, and
high groups achieving a good response after the first dose increase,
and 44.4, 58.3, and 37.5%, respectively, remained non-responders.
Good responders after 12months of enhanced treatment included
25% of no Ifx patients and 0% of low and high Ifx patients, and
50, 77.8, and 71.4% of no, low, and high patients, respectively,
exhibited no response.
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Infliximab and Anti-Infliximab Antibody
Concentrations After Dose Increase
Serum Ifx levels were significantly higher in the high group than
the low and no groups at any studied points (Figure 2A). Ifx
serum levels increased significantly between post-increment (T2)
and 12months (T4) in the high group (p= 0.017) but not in the
low (p= 0.97) or no (p= 1) groups. No free Ifx was present at
12months in 4 of 13 patients (30.7%) in the low group despite
an increase in Ifx dose. Figure 2B shows that ATI levels in the no
group ranged from a basalmedian of 1068.5 (IQR, 377.5–12328.0)
AU/mL to 308.5 (IQR, 0.0–2805.0) AU/mL after 1 year, but it
remained 0AU/mL at all times in the low and high groups. ATI
became positive with no free Ifx drug available in 3 of the 13
patients (23.0%) in the low group with previous negative ATI.
Discussion
The therapeutic effect of an Ifx dose increase was analyzed in three
populations of active non-remitting RA patients who exhibited no
detectable, low and high drug levels. No significant improvement
in disease activity or responder rate was observed after 1 year
of intensified therapy, independently of pre-existing Ifx serum
trough levels.
Our observations are consistent with anti-TNF failure treat-
ment algorithms (7, 8) for two of the populations where a dose
increase was ineffective, i.e., patients with high levels of Ifx and
no response, and patients with non-detectable circulating Ifx due
to the presence of ATI. However, treatment intensification is the
recommended strategy in patients with low trough Ifx to achieve
therapeutic levels of anti-TNF. Isolated analysis of this popula-
tion did not reveal significant disease improvement despite dose
increases in our study, and no significant increase in serum Ifx
levels was achieved. Other studies increased the Ifx dose up to
10mg/kg and found better results. Therefore, we do not conclude
that the outcome would have been different with an increased Ifx
dose up to 10mg/kg. However, the cost to administer this dose is
much higher (17).
Antibodies to infliximab were only detected in patients with
no circulating Ifx because of drug interference with the method
(5). The existence of ATI is highly improbable in patients with
high Ifx levels, but the presence of hidden immunogenicity in
the low Ifx level population may be partially responsible for low
serum drug levels and poor outcomes. No Ifx was detected at
1 year in four patients, and three of these patients expressed ATI.
Other non-immune Ifx clearancemechanisms, such as drug bind-
ing by immune cells expressing Fyc receptors I, II, and III, (18)
naturally occurring anti-mouse antibodies binding infliximab (18,
19), and the “inflammation sink” in which highly expressing TNF
tissues bind anti-TNF drug (18), may also contribute to the low
circulating Ifx in these patients.
Our study has some limitations, such as the retrospective
design, the lack of a pre-determined therapeutic protocol to
increase Ifx dose, and the lack of a control group, but it reflects
the effect of TNF-blocking agents that are used in daily clinical
practice. The observational design of this study was also not
appropriate for this type of analysis.
Conclusion
The enhancing of Ifx therapy is costly and it poses the risk of
increased adverse events (20), which stresses the importance of
exploring Ifx efficacy. Increasing the dose of Ifx to counteract ther-
apeutic response failure was unsuccessful in this study regardless
of the circulating drug levels prior to dose escalation.
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